HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Abstract Background Human epidermal growth factor receptor 2 (HER2) positive breast carcinomas due to HER2 amplification are associated with aggressive behavior and a poor prognosis. Anti-HER2-targeted therapies are widely used to treat HER2-positive breast carcinomas with excellent outcomes. Accura...
Main Authors: | Laura Morsberger, Aparna Pallavajjala, Patty Long, Melanie Hardy, Rebecca Park, Rebecca Parish, Azin Nozari, Ying S. Zou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-11-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-022-02761-1 |
Similar Items
-
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01) -
Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01) -
Correlation of the HER-2 protein expression and other clinicopathological features of ductal infiltrative breast cancer
by: Svjetlana Radović, et al.
Published: (2005-02-01) -
Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
by: Christiane Palm, et al.
Published: (2023-01-01) -
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-04-01)